Anxiolytic effects of mecamylamine in two animal models of anxiety

Experimental and Clinical Psychopharmacology

Volumn 10, Issue 1, 2002, Pages 18-25

  Newman, Mary B ^a   Manresa, John J ^a   Sanberg, Paul R ^a,b   Shytle, R Douglas ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MECAMYLAMINE; NICOTINIC RECEPTOR BLOCKING AGENT;

ANIMAL MODEL; ANXIETY; ARTICLE; CONTROLLED STUDY; MALE; MAZE TEST; NONHUMAN; RAT; SOCIAL INTERACTION; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BEHAVIOR, ANIMAL; INTERPERSONAL RELATIONS; LIGHTING; MALE; MECAMYLAMINE; MODELS, PSYCHOLOGICAL; RATS; RATS, WISTAR;

EID: 0036159574     PISSN: 10641297     EISSN: None     Source Type: Journal    
DOI: 10.1037/1064-1297.10.1.18     Document Type: Article

References (28)

1. [3H]mecamylamine binding to rat brain membranes: Studies with mecamylamine and nicotine analogues
2. Nicotinic receptor agonists exhibit anxiolytic-like effects on the Elevated Plus-Maze Test
3. Elevated cerebrospinal fluid corticotropin-releasing factor in Tourette's syndrome: Comparison to obsessive compulsive disorder and normal controls
4. Enhanced stress responsivity of Tourette syndrome patients undergoing lumbar puncture
5. The interplay of learning and anxiety in the elevated plus-maze
6. Animal models of different anxiety states
7. Neurobiological mechanisms by which nicotine mediates different types of anxiety
8. 1 receptors
9. Role of the dorsomedial hypothalamus in mediating the response to benzodiazepines on trial 2 in the Elevated Plus-Maze Test of anxiety
10. The role of the dorsal hippocampal serotonergic and cholinergic systems in the modulation of anxiety
11. Bimodal modulation by nicotine of anxiety in the social interaction test: Role of the dorsal hippocampus
12. Characterisation of the phenomenon of "one-trial tolerance" to the anxiolytic effect of chlordiazepoxide in the elevated plus-maze
13. "One-trial tolerance" to the anxiolytic actions of benzodiazepines in the elevated plus-maze, or the development of a phobic state?
14. Trial 2 in the elevated plus-maze: A different form of fear?
15. A five minute experience in the elevated plus-maze alters the state of the benzodiazepine receptor in the dorsal raphe nucleus
16. Central actions of nicotine antagonists
17. Corticosterone-attenuating and anxiolytic properties of mecamylamine in the rat
18. Stimulation of nicotinic receptors in the lateral septal nucleus increases anxiety
19. The central and basolateral amygdala differentially mediate the anxiolytic effects of benzodiazepines
20. The neuroanatomical specificity of the anxiolytic effects of intra-septal infusions of midazolam
21. Plus-maze retest profile in mice: Importance of initial stages of trial 1 and response to post-trial cholinergic receptor blockade
22. Influence of prior maze experience on behavior and response to diazepam in the Elevated Plus-Maze and light/dark tests of anxiety in mice
23. Comorbid bipolar disorder in Tourette's syndrome responds to the nicotinic receptor antagonist mecamylamine (Inversine)
24. Mecamylamine in Tourette's syndrome: A two-year retrospective case study
25. Ganglionic blocking properties of 3-methylaminoisocamphane hydrochloride (mecamylamine): A secondary amine
26. Anxiogenic stimuli in the elevated plus-maze
27. Mecamylamine: New therapeutic uses and toxicity/risk profile
28. Involvement of adrenergic and cholinergic systems in nicotine-induced anxiogenesis in mice